ADCs are currently at the forefront of cancer treatment, but persistent drug development challenges call for a new approach.
Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has shown clinically meaningful 'improvement' in the ...
Enhertu improved overall survival versus chemotherapy in HER2-positive metastatic gastric cancer, prompting an interim ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback